Tudor Investment Corp ET AL raised its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 48.1% during the first quarter, according to its most recent filing with the SEC. The firm owned 25,275 shares of the biotechnology company’s stock after buying an additional 8,206 shares during the period. Tudor Investment Corp ET AL owned about 0.17% of Anika Therapeutics worth $1,098,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Louisiana State Employees Retirement System raised its position in Anika Therapeutics by 1.7% in the first quarter. Louisiana State Employees Retirement System now owns 6,000 shares of the biotechnology company’s stock worth $261,000 after buying an additional 100 shares during the last quarter. Atria Investments LLC raised its position in shares of Anika Therapeutics by 13.9% in the first quarter. Atria Investments LLC now owns 5,563 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 679 shares during the last quarter. New England Research & Management Inc. acquired a new position in shares of Anika Therapeutics during the first quarter valued at approximately $447,000. Thrivent Financial for Lutherans raised its position in shares of Anika Therapeutics by 5.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,920 shares of the biotechnology company’s stock valued at $388,000 after buying an additional 390 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky raised its position in shares of Anika Therapeutics by 2.1% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 28,610 shares of the biotechnology company’s stock valued at $1,401,000 after buying an additional 600 shares during the last quarter. Institutional investors own 80.90% of the company’s stock.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 46.47 on Tuesday. The company has a 50-day moving average price of $47.03 and a 200-day moving average price of $47.10. The company has a market cap of $680.97 million, a P/E ratio of 22.43 and a beta of 1.68. Anika Therapeutics Inc. has a 52-week low of $41.38 and a 52-week high of $53.50.
Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.38 by $0.01. The firm had revenue of $23.39 million for the quarter, compared to analysts’ expectations of $23.89 million. Anika Therapeutics had a net margin of 29.81% and a return on equity of 14.29%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.45 EPS. On average, equities analysts predict that Anika Therapeutics Inc. will post $1.91 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Tudor Investment Corp ET AL Buys 8,206 Shares of Anika Therapeutics Inc. (NASDAQ:ANIK)” was originally published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2017/07/18/tudor-investment-corp-et-al-boosts-position-in-anika-therapeutics-inc-anik-updated-updated.html.
Separately, Zacks Investment Research raised Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th.
In other Anika Therapeutics news, CEO Charles H. Sherwood sold 14,201 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $50.03, for a total transaction of $710,476.03. Following the completion of the transaction, the chief executive officer now owns 246,740 shares in the company, valued at approximately $12,344,402.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffery S. Thompson sold 10,725 shares of the firm’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $47.39, for a total value of $508,257.75. Following the transaction, the director now owns 15,845 shares of the company’s stock, valued at approximately $750,894.55. The disclosure for this sale can be found here. Company insiders own 6.57% of the company’s stock.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.